DEA Temporarily Extends Telehealth Prescribing Rules for Controlled Substances
The DEA has prolonged the telehealth flexibilities introduced during the pandemic, enabling healthcare providers to prescribe controlled substances via telemedicine. Initially set to end in May, this extension until November responds to overwhelming public concern, with over 38,000 comments highlighting worries about proposed restrictions on telehealth-controlled substance prescriptions. This decision is supported by organizations such as the American Telemedicine Association and the American Hospital Association, who argue that requiring in-person visits could hinder access to essential care, especially for those struggling with opioid use disorders, which the pandemic has compounded. As we look ahead to 2024, a critical year for telehealth, this extension ensures that patients can conveniently access necessary care, reflecting the evolving landscape of healthcare accessibility.
DEA Temporarily Extends Telehealth Prescribing Rules for Controlled Substances (Olsen, Healthcare Dive, 10/9).
